Mito-fisetin mF7 

Mito-fisetin mF7 is a lipophilic derivative of Fisetin (HY-N0182). Mito-fisetin mF7 interacts with AKT and Bcl-2, limiting their stability and functionality. Mito-fisetin mF7 stimulates impairs mitochondrial function and reduces metabolic activity of cancer cells. Mito-fisetin mF7 can be used for the research of ER-positive breast cancer^[1].

Mito-fisetin mF7 (1-10 μM; 24 h) reduces metabolic activity of ER-positive HCC1500, CAMA-1, HCC1428, and ZR-75-30 breast cancer cells, while normal BJ fibroblasts and MCF10F cells are less sensitive^[1].
Mito-fisetin mF7 (5 μM; 6 h) disrupts mitochondrial function in proliferating HCC1428 breast cancer cells^[1].
Mito-fisetin mF7 (0.01-5 μM; overnight at 37 °C) directly interacts with recombinant human AKT and Bcl-2 proteins, reducing detectable protein levels as measured by dot-blot densitometry^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

936.76

C₅₂H₄₂IO₇P

3106880-06-9

O=C(C)OC1=C(C2=CC3=C(OC(C4=CC=CC=C4)(C5=CC=CC=C5)O3)C=C2)OC6=CC(OCCCC[P+](C7=CC=CC=C7)(C8=CC=CC=C8)C9=CC=CC=C9)=CC=C6C1=O.[I-]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rzeszutek I, et al. New Mitochondria-Targeted Fisetin Derivative Compromises Mitophagy and Limits Survival of Drug-Induced Senescent Breast Cancer Cells. J Med Chem. 2024;67(19):17676-17689.  [Content Brief]